The beneficial effects of closed-loop insulin delivery in patients with highly unstable type 1 diabetes eligible for islet transplantation are maintained over 6 months: An extension study of the DBLHU-WP10 trial

Pierre-Yves Benhamou; Sandrine Lablanche; Anne Vambergue; Sylvie Pou; Stéphanie Madrolle; Hector Romero-Ugalde; Sylvia Franc; Guillaume Charpentier

doi:10.1111/dom.14654

The beneficial effects of closed-loop insulin delivery in patients with highly unstable type 1 diabetes eligible for islet transplantation are maintained over 6 months: An extension study of the DBLHU-WP10 trial

Diabetes Obes Metab. 2022 May;24(5):956-961. doi: 10.1111/dom.14654. Epub 2022 Feb 21.

Authors

Pierre-Yves Benhamou¹, Sandrine Lablanche¹, Anne Vambergue², Sylvie Pou³, Stéphanie Madrolle³, Hector Romero-Ugalde³, Sylvia Franc^{4

5}, Guillaume Charpentier^{4

5}

Affiliations

¹ Department of Endocrinology, Grenoble University Hospital, Grenoble Alpes University, Grenoble, France.
² Department of Endocrinology, Lille University Hospital, Lille, France.
³ Diabeloop SA, Paris, France.
⁴ CERITD (Center for Study and Research for Improvement of the Treatment of Diabetes), Bioparc-Genopole Evry-Corbeil, Evry, France.
⁵ Department of Diabetes and Endocrinology, Sud-Francilien Hospital, Corbeil, France.

PMID: 35099098
DOI: 10.1111/dom.14654

No abstract available

Keywords: artificial pancreas; brittle diabetes; closed-loop; hypoglycaemia unawareness; problematic hypoglycaemia; severe hypoglycaemia; type 1 diabetes; unstable diabetes.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 1* / drug therapy
Diabetes Mellitus, Type 1* / etiology
Humans
Hypoglycemic Agents / therapeutic use
Insulin / therapeutic use
Insulin Infusion Systems / adverse effects
Islets of Langerhans Transplantation*

Substances

Blood Glucose
Hypoglycemic Agents
Insulin